<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105415</url>
  </required_header>
  <id_info>
    <org_study_id>13-000506</org_study_id>
    <nct_id>NCT02105415</nct_id>
  </id_info>
  <brief_title>Ketamine / Propofol Admixture &quot;Ketofol&quot; at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial</brief_title>
  <acronym>KEEP PACE</acronym>
  <official_title>Ketamine / Propofol Admixture &quot;Ketofol&quot; at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that a Ketamine / Propofol mixture will produce more stable
      hemodynamics as compared to Etomidate during emergent intubations in the intensive care unit.
      Patients that require a breathing tube to be placed in the ICU will be randomized to receIve
      either a Ketamine / Propofol mixture or Etomidate for sedation in order to place the
      breathing tube.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endotracheal intubation is a procedure that may cause significant hemodynamic perturbations
      and can severely impact the outcome of the critically ill. To ensure a safe outcome during
      this particular procedure, there are many factors that the clinician is faced with. One
      decision that confronts the critical care physician involves the correct combination of
      medications with which to facilitate such a safe outcome. Given the reported hemodynamic
      stability, etomidate is a medication that is chosen by many providers in this particular
      situation. However, its association with a possible increase in mortality makes it less than
      ideal for a number of critical care physicians. In recent years, an admixture of propofol and
      ketamine has been studied that demonstrates hemodynamic stability based on the balancing of
      the hemodynamic effects of these two individual agents alone. This novel medication
      combination, sometimes referred to as &quot;ketofol&quot;, may offer a valuable alternative to the
      critical care physician. Therefore, a randomized parallel-group clinical trial of adult
      critically ill patients admitted to a medical and/or surgical intensive care unit at Mayo
      Clinic Rochester who meet the criteria designated below for which urgent and/or emergent
      intubation is needed will receive one of two interventions based on stratified randomization.
      The &quot;active&quot; intervention arm will receive ketamine/propofol (ketofol) to facilitate
      endotracheal intubation. The comparison arm will receive etomidate. The primary outcome will
      focus on hemodynamic data recorded during the first 5 minutes post-administration with
      secondary outcomes looking at hemodynamic data at 10 and 15 minutes and addressing intensive
      care unit length of stay, mortality, adrenal function, and vasoactive medication use, among
      others.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Arterial Pressure</measure>
    <time_frame>baseline and every 5 minutes up to 15 minutes minutes post study drug administration</time_frame>
    <description>Mean arterial pressure for the ketamine/propofol group at a 1:1 dose ratio compared to the etomidate group within the first 15 minutes post-administration in patients in need of urgent and/or emergent endotracheal intubation, as defined by any intubation within the intensive care unit excluding intubations for elective procedural events and codes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Hospital Discharge or Day 28, whichever comes first</time_frame>
    <description>In-hospital/28 day mortality among patients in ketamine/propofol combination compared to in-hospital/28-day mortality in etomidate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor Use</measure>
    <time_frame>up to 24 hours post study drug administration</time_frame>
    <description>The use of vasoactive medications to restore the blood pressure post-administration in the ketamine/propofol combination as compared to the etomidate group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adrenal Insufficiency</measure>
    <time_frame>up to 24 hours post study drug administration</time_frame>
    <description>Incidence of adrenal insufficiency between ketamine/propofol admixture and etomidate. Adrenal insuffiency was evaluated with co-syntropin stimulation test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilation Free Days</measure>
    <time_frame>hospital discharge or day 28, whichever comes first</time_frame>
    <description>comparison of mechanical ventilation free days between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Product Transfusions</measure>
    <time_frame>hospital discharge or day 28, whichever comes first</time_frame>
    <description>blood product transfusions [Red Blood Cells vs. non-Red Blood Cells] between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Free Days</measure>
    <time_frame>hospital discharge or day 28, whichever comes first</time_frame>
    <description>comparison of intensive care unit free days between the two groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU</measure>
    <time_frame>up to 24 hours post study drug administration</time_frame>
    <description>Comparison of number of participants who were positive for delirium using CAM-ICU between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weight based dose of 0.15mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine / Propofol Admixture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine / Propofol Admixture</intervention_name>
    <arm_group_label>Ketamine / Propofol Admixture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <arm_group_label>Etomidate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Surgical or medical intensive care unity patients requiring endotracheal intubation

          -  Consulting physician agrees to study plan and will follow drug randomization

        Exclusion Criteria:

          -  Known intracranial pathology

          -  Known chronic opiate-dependence

          -  Received continuous sedative infusion in the last 24 hours

          -  Known severe psychiatric illness

          -  Known egg allergies

          -  Known contraindication to fentanyl, midazolam, ketamine, propofol or etomidate

          -  Intubation in which standard practice is not to use sedation

          -  No known documented weight or weight greater than 140 kg or less than 30 kg

          -  Prior participation in the study

          -  Of childbearing age (18-50) with no known negative pregnancy test on this admission.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan J Smischney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <results_first_submitted>November 26, 2018</results_first_submitted>
  <results_first_submitted_qc>December 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2019</results_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Nathan J. Smischney</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Critical care</keyword>
  <keyword>Emergent</keyword>
  <keyword>Etomidate</keyword>
  <keyword>Hemodynamics</keyword>
  <keyword>Intensive care unit</keyword>
  <keyword>Intubation</keyword>
  <keyword>Ketamine-Propofol admixture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Etomidate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02105415/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etomidate</title>
          <description>Etomidate 0.15mg/kg weight based dose</description>
        </group>
        <group group_id="P2">
          <title>Ketamine / Propofol Admixture</title>
          <description>Ketamine / Propofol Admixture; weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etomidate</title>
          <description>Etomidate 0.15mg/kg weight based dose</description>
        </group>
        <group group_id="B2">
          <title>Ketamine / Propofol Admixture</title>
          <description>Ketamine / Propofol Admixture weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="18.3"/>
                    <measurement group_id="B2" value="62.1" spread="17.2"/>
                    <measurement group_id="B3" value="61.1" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Arterial Pressure</title>
        <description>Mean arterial pressure for the ketamine/propofol group at a 1:1 dose ratio compared to the etomidate group within the first 15 minutes post-administration in patients in need of urgent and/or emergent endotracheal intubation, as defined by any intubation within the intensive care unit excluding intubations for elective procedural events and codes.</description>
        <time_frame>baseline and every 5 minutes up to 15 minutes minutes post study drug administration</time_frame>
        <population>Data are presented for patients who had blood pressure measurements at baseline (within 15 minutes prior to study drug administration).</population>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate 0.15mg/kg weight based dose</description>
          </group>
          <group group_id="O2">
            <title>Ketamine / Propofol Admixture</title>
            <description>Ketamine / Propofol Admixture weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Pressure</title>
          <description>Mean arterial pressure for the ketamine/propofol group at a 1:1 dose ratio compared to the etomidate group within the first 15 minutes post-administration in patients in need of urgent and/or emergent endotracheal intubation, as defined by any intubation within the intensive care unit excluding intubations for elective procedural events and codes.</description>
          <population>Data are presented for patients who had blood pressure measurements at baseline (within 15 minutes prior to study drug administration).</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8" spread="17.9"/>
                    <measurement group_id="O2" value="80.9" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7" spread="17.2"/>
                    <measurement group_id="O2" value="77.6" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" spread="20.0"/>
                    <measurement group_id="O2" value="75.3" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1" spread="19.5"/>
                    <measurement group_id="O2" value="75.5" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>5 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.385</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>10 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.241</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>15 minutes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.802</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>In-hospital/28 day mortality among patients in ketamine/propofol combination compared to in-hospital/28-day mortality in etomidate.</description>
        <time_frame>Hospital Discharge or Day 28, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate 0.15mg/kg weight based dose</description>
          </group>
          <group group_id="O2">
            <title>Ketamine / Propofol Admixture</title>
            <description>Ketamine / Propofol Admixture weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>In-hospital/28 day mortality among patients in ketamine/propofol combination compared to in-hospital/28-day mortality in etomidate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.605</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vasopressor Use</title>
        <description>The use of vasoactive medications to restore the blood pressure post-administration in the ketamine/propofol combination as compared to the etomidate group.</description>
        <time_frame>up to 24 hours post study drug administration</time_frame>
        <population>Data are presented for patients who had vasopressor data within the time frame</population>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate 0.15mg/kg weight based dose</description>
          </group>
          <group group_id="O2">
            <title>Ketamine / Propofol Admixture</title>
            <description>Ketamine / Propofol Admixture; weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol.</description>
          </group>
        </group_list>
        <measure>
          <title>Vasopressor Use</title>
          <description>The use of vasoactive medications to restore the blood pressure post-administration in the ketamine/propofol combination as compared to the etomidate group.</description>
          <population>Data are presented for patients who had vasopressor data within the time frame</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treament</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New-onset pressors (within 3 minutes)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed-onset pressors (within 24 hours)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre-treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>New-onset pressors (within 3 minutes)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Delayed-onset pressors (within 24 hrs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.691</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adrenal Insufficiency</title>
        <description>Incidence of adrenal insufficiency between ketamine/propofol admixture and etomidate. Adrenal insuffiency was evaluated with co-syntropin stimulation test.</description>
        <time_frame>up to 24 hours post study drug administration</time_frame>
        <population>A secondary outcome included adrenal testing in a subset of patients. Thus, cortisol levels were available for 29 subjects at 3 and 5 hours and 30 subjects at 23 and 25 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Etomidate (3-5 Hours)</title>
            <description>Cortisol levels at 3-5 hours</description>
          </group>
          <group group_id="O2">
            <title>Ketamine/Propofol Admixture (3-5 Hours)</title>
            <description>Cortisol levels at 3-5 hours</description>
          </group>
          <group group_id="O3">
            <title>Etomidate (23-25 Hours)</title>
            <description>Cortisol levels at 23-25 hours</description>
          </group>
          <group group_id="O4">
            <title>Ketamine/Propofol Admixture (23-25 Hours)</title>
            <description>Cortisol levels at 23-25 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adrenal Insufficiency</title>
          <description>Incidence of adrenal insufficiency between ketamine/propofol admixture and etomidate. Adrenal insuffiency was evaluated with co-syntropin stimulation test.</description>
          <population>A secondary outcome included adrenal testing in a subset of patients. Thus, cortisol levels were available for 29 subjects at 3 and 5 hours and 30 subjects at 23 and 25 hours.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mechanical Ventilation Free Days</title>
        <description>comparison of mechanical ventilation free days between the two groups</description>
        <time_frame>hospital discharge or day 28, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate 0.15mg/kg weight based dose</description>
          </group>
          <group group_id="O2">
            <title>Ketamine / Propofol Admixture</title>
            <description>Ketamine / Propofol Admixture; weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol.</description>
          </group>
        </group_list>
        <measure>
          <title>Mechanical Ventilation Free Days</title>
          <description>comparison of mechanical ventilation free days between the two groups</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="0" upper_limit="25"/>
                    <measurement group_id="O2" value="20" lower_limit="0" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.911</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Product Transfusions</title>
        <description>blood product transfusions [Red Blood Cells vs. non-Red Blood Cells] between the two groups</description>
        <time_frame>hospital discharge or day 28, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate 0.15mg/kg weight based dose</description>
          </group>
          <group group_id="O2">
            <title>Ketamine / Propofol Admixture</title>
            <description>Ketamine / Propofol Admixture; weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Product Transfusions</title>
          <description>blood product transfusions [Red Blood Cells vs. non-Red Blood Cells] between the two groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red blood cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-red blood cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colloid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Red blood cell</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-red blood cell</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Colloid</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.502</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit Free Days</title>
        <description>comparison of intensive care unit free days between the two groups</description>
        <time_frame>hospital discharge or day 28, whichever comes first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate 0.15mg/kg weight based dose</description>
          </group>
          <group group_id="O2">
            <title>Ketamine / Propofol Admixture</title>
            <description>Ketamine / Propofol Admixture weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit Free Days</title>
          <description>comparison of intensive care unit free days between the two groups</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="0" upper_limit="23"/>
                    <measurement group_id="O2" value="17" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.994</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU</title>
        <description>Comparison of number of participants who were positive for delirium using CAM-ICU between groups</description>
        <time_frame>up to 24 hours post study drug administration</time_frame>
        <population>The analysis of new onset delirium was restricted to subjects (54 etomidate, 62 KPA) who did not experience delirium pre-study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Etomidate</title>
            <description>Etomidate 0.15mg/kg weight based dose</description>
          </group>
          <group group_id="O2">
            <title>Ketamine / Propofol Admixture</title>
            <description>Ketamine / Propofol Admixture; weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU</title>
          <description>Comparison of number of participants who were positive for delirium using CAM-ICU between groups</description>
          <population>The analysis of new onset delirium was restricted to subjects (54 etomidate, 62 KPA) who did not experience delirium pre-study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.233</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Given the context of the study and the emergent nature in which the interventions were conducted, adverse events were collected up to 72 hours after enrollment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etomidate</title>
          <description>Etomidate 0.15mg/kg weight based dose</description>
        </group>
        <group group_id="E2">
          <title>Ketamine / Propofol Admixture</title>
          <description>Ketamine / Propofol Admixture weight based dose 0.5 mg/kg ketamine and 0.5 mg/kg propofol</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Severe hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>arrythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>IV infiltration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Multi organ failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting/Aspiration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intubation Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Single center study with non-blinded interventions and non-controlled co-interventions all of which can impact hemodynamics. Selection bias with 92 non-enrollees.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Nathan Smischney</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-4305</phone>
      <email>smischney.nathan@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

